Preview

Problems of Endocrinology

Advanced search

Molecular-genetic, immunological bases and prophylaxis of diabetes mellitus in children

https://doi.org/10.14341/probl20115719-18

Abstract

Since the autoimmune nature of type 1 diabetes mellitus came to become known some 40 years ago, continuous investigations have been carried out in an attempt to improve approaches to prognostication of this disease and develop new safe and efficacious methods for its prevention. For all that, many aspects of diabetes pathogenesis still remain far from clear. In most cases (roughly 85%), type 1 diabetes mellitus (DM1) develops sporadically in the absence of a relevant familial or hereditary history of this condition. Accordingly, the first-degree relatives account for only 15% of all DM1 patients. The risk of development of DM1 in the Russian population estimated by the researchers of the Children' Department, Endocrinological Research Centre, is relatively low (0.2%). It depends on many factors, such as the number of ill and healthy relatives, the chronological age of a given patient and the age of onset of clinical manifestations in his (her) relatives. Type 1 diabetes-predisposing and protective haplotypes were identified in the Russian population based on the results of molecular-genetic studies involving 599 children and adolescents with DM1. These and immunological data were used to distinguish between risk groups in the families of diabetic patients and the rationale was proposed for the dynamic follow-up of these subjects. It is concluded that estimation of the risk of type 1 diabetes mellitus based on the results of molecular-genetic studies and monitoring immunological markers constitutes the first step in the elaboration of preventive measures designed to prevent or delay the development of the disease.

About the Author

E V Titovich



References

1. Дедов И.И., Шестакова М.В. Сахарный диабет. Руководство для врачей. М 2003.

2. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:10:619-633.

3. Atkinson M.A. ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease. Diabetes 2005;54:5:1253-1263.

4. Дедов И.И., Кураева Т.Л., Петеркова В.А., Щербачев Л.Н. Сахарный диабет у детей и подростков. М 2002.

5. Eisenbarth G.S. Insulin autoimmunity: immunogenetics/immunopathogenesis of type 1A diabetes. Ann N Y Acad Sci 2003;1005:109-118.

6. Petrone A., Spoletini M., Zampetti S. et al. The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual beta-cell function and worse metabolic control. Diabet Care 2008;31:6:1214-1218.

7. Steele C., Hagopian W.A., Gitelman S. et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:2:426-433.

8. Holland A.M., Góñez L.J., Harrison L.C. Progenitor cells in the adult pancreas. Diabetes Metab Res Rev 2004;20:1:13-27.

9. Greenbaum C.J., Sears K.L., Kahn S.E., Palmer J.P. Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study. Diabetes 1999;48:1:170-175.

10. William E., Harris N., Schatz D. Immunological markers in the diagnosis and prediction of autoimmune type 1a diabetes. Clin Diabet 2002;20:4:183-191.

11. Кураева Т.Л., Петеркова В.А., Носиков В.В. и др. Возможности прогнозирования инсулинзависимого сахарного диабета в семьях больных на основе исследования генетических маркеров. Сахарный диабет 1998;1:34-38.

12. Дедов И.И., Петеркова В.А., Кураева Т.Л. и др. Прогнозирование и профилактика сахарного диабета в детском возрасте. М 2009;55.

13. Bingley P.J., Gale E.A.; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006;49:5:881-890.

14. Skyler J.S., Krischer J.P., Wolfsdorf J. et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabet Care 2005;28:5:1068-1076.

15. Harjutsalo V., Lammi N., Karvonen M., Groop P.H. Age at onset of type 1 diabetes in parents and recurrence risk in offspring. Diabetes 2010;59:1:210-214.

16. Decochez K., Truyen I., van der Auwera B. et al. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 2005;48:4:687-694.

17. House D.V., Winter W.E. Autoimmune diabetes: the role of autoantibody markers in the prediction and prevention of insulin diabetes mellitus. Lab Clin North Am 1997;17:499-545.

18. Wenzlau J.M., Juhl K., Yu L. et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Diabetes 2007;104:43:17040-17045.

19. Orban T., Sosenko J.M., Cuthbertson D. et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabet Care 2009;32:12:2269-2274.

20. Siljander H.T., Simell S., Hekkala A. et al. Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 2009;58:12:2835-2842.

21. Siljander H.T., Veijola R., Reunanen A. et al. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia 2007;50:11:2272-2275.

22. Fourlanos S., Varney M.D., Tait B.D. et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabet Care 2008;31:8:1546-1549.

23. Rewers M., Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabet Care 2009;32:10:1769-1782.

24. Bresson D., von Herrath M. Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside. Diabet Care 2009;32:10:1753-1768.

25. TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabet 2007;8:3:117-137.

26. Schmid S., Buuck D., Knopff A. et al. BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten. Diabetologia 2004;47:6:1130-1131.

27. Norris J.M., Yin X., Lamb M.M. et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007;298:12:1420-1428.

28. Agardh C.D., Lynch K.F., Palmér M. et al. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009;52:7:1363-1368.

29. Ludvigsson J., Faresjö M., Hjorth M. et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:18:1909-1920.

30. Raz I., Elias D., Avron A. et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358:9295:1749-1753.

31. Lazar L., Ofan R., Weintrob N. et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabet Metab Res Rev 2007;23:4:286-291.

32. Herold K.C., Gitelman S.E., Masharani U. et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:6:1763-1769.

33. Mastrandrea L., Yu J., Behrens T. et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabet Care 2009;32:7:1244-1249.

34. Rother K.I., Brown R.J., Morales M.M. et al. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabet Care 2009;32:7:1250-1255.

35. Rother K.I., Spain L.M., Wesley R.A. et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabet Care 2009;32:12:2251-2257.

36. Radtke M.A., Nermoen I., Kollind M. et al. Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta} - cell function and autoimmunity but improves glycemic control. Diabet Care 2010;33:3:589-594.

37. Gottlieb P.A., Quinlan S., Krause-Steinrauf H. et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabet Care 2010;33:4:826-832.


Review

For citations:


Titovich E.V. Molecular-genetic, immunological bases and prophylaxis of diabetes mellitus in children. Problems of Endocrinology. 2011;57(1):9-18. https://doi.org/10.14341/probl20115719-18

Views: 915


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)